Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer | Zendy

Leena Gandhi | Zendy; Delvys RodríguezAbreu | Zendy; Shirish M. Gadgeel | Zendy; Emilio Esteban | Zendy; Enriqueta Felip | Zendy; Flávia De Angelis | Zendy; Manuel Dómine | Zendy; Philip R. Clingan | Zendy; Maximilian J. Hochmair | Zendy; Steven Powell | Zendy; Susanna Y. Cheng | Zendy; Helge Bischoff | Zendy; Nir Peled | Zendy; Francesco Grossi | Zendy; Ross Jennens | Zendy; Martin Reck | Zendy; Rina Hui | Zendy; Edward B. Garon | Zendy; Michael Boyer | Zendy; Belén RubioViqueira | Zendy; Silvia Novello | Zendy; Takayasu Kurata | Zendy; Jhanelle E. Gray | Zendy; John Vida | Zendy; Ziwen Wei | Zendy; Jing Yang | Zendy; Harry Raftopoulos | Zendy; M. Catherine Pietanza | Zendy; Marina Chiara Garassino | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Author(s) -

Leena Gandhi,

Delvys RodríguezAbreu,

Shirish M. Gadgeel,

Emilio Esteban,

Enriqueta Felip,

Flávia De Angelis,

Manuel Dómine,

Philip R. Clingan,

Maximilian J. Hochmair,

Steven Powell,

Susanna Y. Cheng,

Helge Bischoff,

Nir Peled,

Francesco Grossi,

Ross Jennens,

Martin Reck,

Rina Hui,

Edward B. Garon,

Michael Boyer,

Belén RubioViqueira,

Silvia Novello,

Takayasu Kurata,

Jhanelle E. Gray,

John Vida,

Ziwen Wei,

Jing Yang,

Harry Raftopoulos,

M. Catherine Pietanza,

Marina Chiara Garassino

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1801005

Subject(s) - pembrolizumab , chemotherapy , lung cancer , medicine , oncology , cancer , immunotherapy

First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the first-line treatment of choice. The addition of pembrolizumab to chemotherapy resulted in significantly higher rates of response and longer progression-free survival than chemotherapy alone in a phase 2 trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research